A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced ER+/HER2+ BC. Inhibition of CDK4/6 and HER2 results in synergistic cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Ademuyiwa, Foluso O., Northfelt, Donald W., O’Connor, Tracey, Levine, Ellis, Luo, Jingqin, Tao, Yu, Hoog, Jeremy, Laury, Marie L., Summa, Tracy, Hammerschmidt, Trish, Guo, Zhanfang, Frith, Ashley, Weilbaecher, Katherine, Opyrchal, Mateusz, Aft, Rebecca, Clifton, Katherine, Suresh, Rama, Bagegni, Nusayba, Hagemann, Ian S., Iglesia, Michael D., Ma, Cynthia X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822956/
https://www.ncbi.nlm.nih.gov/pubmed/36609389
http://dx.doi.org/10.1038/s41523-022-00504-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822956/
https://www.ncbi.nlm.nih.gov/pubmed/36609389
http://dx.doi.org/10.1038/s41523-022-00504-z

Ejemplares similares